Drug intelligence / Profile preview

probiotic suppositories

Development stage: Preclinical
Lead developer: Institute Torlak
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Rectal, Vaginal

Overview

Probiotic suppositories is a live biotherapeutic product currently in preclinical development by the Institute of Virology, Vaccines and Sera "Torlak" (Torlak Institute) in Serbia. The product is designed for local administration, either rectally or vaginally, to deliver beneficial microorganisms intended to restore microbial balance and treat local dysbiosis or infections. As a preclinical asset, specific bacterial strains and primary clinical indications have not yet been disclosed by the developer, though such formulations are typically investigated for conditions like bacterial vaginosis or inflammatory bowel disease.

Other names: Probiotic suppositories

Targets

HDAC (HDAC family)UPK1A (Uroplakin-1a)Bacterial cell envelope

Beyond the preview

Go deeper on probiotic suppositories.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on probiotic suppositories.